BRPI0518795A2 - mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio - Google Patents

mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio

Info

Publication number
BRPI0518795A2
BRPI0518795A2 BRPI0518795-8A BRPI0518795A BRPI0518795A2 BR PI0518795 A2 BRPI0518795 A2 BR PI0518795A2 BR PI0518795 A BRPI0518795 A BR PI0518795A BR PI0518795 A2 BRPI0518795 A2 BR PI0518795A2
Authority
BR
Brazil
Prior art keywords
therapeutic treatment
inflammatory
individual
determining
a3ar
Prior art date
Application number
BRPI0518795-8A
Other languages
English (en)
Inventor
Pnina Fishman
Sara Bar-Yehuda
Lea Madi
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518795(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of BRPI0518795A2 publication Critical patent/BRPI0518795A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

MÉTODOS PARA DETERMINAR A EFICÁCIA DE UM TRATAMENTO TERAPÊUTICO ANTI-INFLAMATàRIO DE UM INDIVÍDUO E PARA SELECIONAR UM INDIVÍDUO QUE SOFRE DE UMA CERTA DOENÇA INFLAMATàRIA PARA RECEBER TRATAMENTO TERAPÊUTICO ANTI-INFLAMATàRIO. O estado inflamatório em um individuo é examinado determinando-se o nível de expressão do receptor de adenosina A~ 3~ (A~ 3~AR) em leucócitos (WBC), por exemplo, circulação de WBCs, do individuo. Um alto nível de expressão de A~ 3~AR é indicativo de um estado inflamatório no individuo. Este ensaio pode ser usado para determinar a gravidade da inflamação em um indivíduo e monitorar a eficácia de tratamento anti- inflamatório. Também, o nível de expressão pode ser usado para selecionar indivíduos que receberão um tratamento anti-inflamatório que compreende um agonista de A~ 3~AR.
BRPI0518795-8A 2004-12-02 2005-11-30 mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio BRPI0518795A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63219804P 2004-12-02 2004-12-02
US65771805P 2005-03-03 2005-03-03
PCT/IL2005/001279 WO2006059327A1 (en) 2004-12-02 2005-11-30 A biological marker for inflammation

Publications (1)

Publication Number Publication Date
BRPI0518795A2 true BRPI0518795A2 (pt) 2008-12-09

Family

ID=35708899

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0518777-0A BRPI0518777A2 (pt) 2004-12-02 2005-11-30 usos de um agonista do receptor de adenosina a3 (a3ar) e de metotrexato (mtx)
BRPI0518795-8A BRPI0518795A2 (pt) 2004-12-02 2005-11-30 mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0518777-0A BRPI0518777A2 (pt) 2004-12-02 2005-11-30 usos de um agonista do receptor de adenosina a3 (a3ar) e de metotrexato (mtx)

Country Status (13)

Country Link
US (3) US20080056992A1 (pt)
EP (2) EP1817079B1 (pt)
JP (2) JP4842964B2 (pt)
KR (2) KR20070100261A (pt)
AT (2) ATE402739T1 (pt)
AU (2) AU2005310873B2 (pt)
BR (2) BRPI0518777A2 (pt)
CA (2) CA2586773C (pt)
DE (2) DE602005015135D1 (pt)
DK (1) DK1817079T3 (pt)
ES (2) ES2327435T3 (pt)
MX (2) MX2007006500A (pt)
WO (2) WO2006059328A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043054A1 (en) * 2005-10-12 2007-04-19 Can-Fite Biopharma Ltd. Treatment and monitoring disease state of liver cancer
KR101101252B1 (ko) * 2005-11-30 2012-01-04 캔-파이트 바이오파마 리미티드 골관절염 치료를 위한 ａ3 아데노신 수용체 아고니스트의용도
US20080183101A1 (en) * 2006-08-17 2008-07-31 Jonathan Richard Stonehouse Salivary analysis
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008056361A1 (en) * 2006-11-09 2008-05-15 Can-Fite Biopharma Ltd. A biological marker for psoriasis
ES2641190T3 (es) 2007-03-14 2017-11-08 Can-Fite Biopharma Ltd. Procedimiento de síntesis de IB-MECA
IL200753A (en) * 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
EP2542242A1 (en) * 2010-03-03 2013-01-09 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services A3ar agonists for the treatment of uveitis
WO2011158904A1 (ja) * 2010-06-18 2011-12-22 株式会社林原生物化学研究所 アデノシンｎ１－オキシドを有効成分として含有する炎症性疾患治療剤
KR102095284B1 (ko) 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985005031A1 (en) 1984-05-09 1985-11-21 The Australian National University A method for the modulation of the immune response
AU5182500A (en) 1996-08-01 2000-10-26 Kennedy Institute Of Rheumatology, The Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
AU5696198A (en) 1996-12-06 1998-06-29 Amgen, Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US20020179549A1 (en) * 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
JP2004135657A (ja) * 2002-08-21 2004-05-13 Kyowa Hakko Kogyo Co Ltd ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物
JP2006503564A (ja) * 2002-10-21 2006-02-02 カン−フィテ・バイオファーマ・リミテッド 治療学的処置のための診断マーカー
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
US20040137477A1 (en) * 2002-10-22 2004-07-15 Can-Fite Biopharma, Ltd. A3AR as a marker for a diseased state
WO2004045627A1 (en) * 2002-11-19 2004-06-03 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
US20050074451A1 (en) 2003-06-25 2005-04-07 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
US7465715B2 (en) 2003-12-29 2008-12-16 Can-Fite Biopharma, Ltd. Method for treatment of multiple sclerosis

Also Published As

Publication number Publication date
ES2327435T3 (es) 2009-10-29
US8541182B2 (en) 2013-09-24
EP1817079A1 (en) 2007-08-15
JP4842964B2 (ja) 2011-12-21
AU2005310874A1 (en) 2006-06-08
ATE402739T1 (de) 2008-08-15
WO2006059328A1 (en) 2006-06-08
ATE434762T1 (de) 2009-07-15
DE602005008639D1 (de) 2008-09-11
AU2005310873B2 (en) 2008-11-27
MX2007006501A (es) 2007-07-13
JP2008521883A (ja) 2008-06-26
KR20070100261A (ko) 2007-10-10
DK1817079T3 (da) 2008-11-17
EP1817079B1 (en) 2008-07-30
WO2006059327A1 (en) 2006-06-08
EP1817589A1 (en) 2007-08-15
CA2586773A1 (en) 2006-06-08
AU2005310874B2 (en) 2008-11-27
ES2309817T3 (es) 2008-12-16
US20130345163A1 (en) 2013-12-26
JP2008522182A (ja) 2008-06-26
KR20070090222A (ko) 2007-09-05
EP1817589B1 (en) 2009-06-24
US20100256084A1 (en) 2010-10-07
BRPI0518777A2 (pt) 2008-12-09
CA2586774A1 (en) 2006-06-08
AU2005310873A1 (en) 2006-06-08
DE602005015135D1 (de) 2009-08-06
CA2586773C (en) 2018-03-27
US20080056992A1 (en) 2008-03-06
MX2007006500A (es) 2007-07-13

Similar Documents

Publication Publication Date Title
BRPI0518795A2 (pt) mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
Brown et al. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers
Wright et al. Mean systolic and diastolic blood pressure in adults aged 18 and over in the United States, 2001–2008
Mezil et al. Response of bone turnover markers and cytokines to high-intensity low-impact exercise
WO2007123976A3 (en) Antibody profiling for determination of patient responsiveness
US11814681B2 (en) Method for predicting a subjects response to SLC modulator therapy
NZ584642A (en) Factor involved in latent infection with herpesvirus, and use thereof
dos Santos Jaques et al. Activities of enzymes that hydrolyze adenine nucleotides in lymphocytes from patients with rheumatoid arthritis
MA30786B1 (fr) Procede d'optimisation de traitement de la leucemie philadelphie positive avec des inhibiteurs de tyrosine kinase abl.
van Haaften et al. The initial repair response of articular cartilage after mechanically induced damage
Derman et al. Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients
BR0001794A (pt) Aplicação de fitosteróides (e seus isÈmeros), ácidofólico, cianocobalamina e piridoxina em fibrasdietéticas (alimentares)
Brownlow et al. Disability and mental health of patients waiting for total hip replacement.
Geng et al. Ethanol increases mechanical pain sensitivity in rats via activation of GABA A receptors in medial prefrontal cortex
BR0014742A (pt) Método para a inibição de uma resposta pró-inflamatória de uma célula mononuclear e célula polimorfonuclear de sangue periférico humano, ou uma célula de tecido fixado, quando contactada com um agente pró-inflamatório, complexo de receptor, e, método para a identificação de um agente de modificação de via de sinal de proteìna g quinase
MXPA05008805A (es) Metodo de tratamiento de enfermedad utilizando un antagonista de receptor de adenosina a1.
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target
BRPI0407213A (pt) Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados
Marks Physiological systems under pressure
BR0015055A (pt) Método de aumento estimulação ou potencialização da diferenciação de células t, método de tratamento de uma doença mediada por th1 em um mamìfero, método de prevenir, inibir ou atenuar a diferenciação de céluas t, método de tratamento de uma doença mediada por th2, em um mamìfero, método de determinação da presença de polipeptìdeo tccr em uma célula, método de diagnóstico de doenças mediadas por th1 ou mediadas por th2 em um mamìfero, método de identificação de compostos capazes de inibir a expressão de polipeptìdeos tccr e método para identificação de compostos capazes de inibir a atividade biológica de polipeptìdeo tccr, uso de antagonistas e agonistas de polipeptìdeos tccr
Yeung et al. Exercise improves hemodynamic profiles and increases red blood cell concentrations of purine nucleotides in a rodent model
White et al. Delirium and C-reactive protein
Orio et al. The polycystic ovary syndrome: an example of obesity-related cardiovascular complication affecting young women
Huber Splenic Control of Cardiovascular Homeostasis: the role of the spleen in the pathogenesis of cardiovascular disease
Calleja et al. Chronic graft-versus-recipient disease: systematic review of joint and fascial involvement

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13, 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]